1-4 of 4
Keywords: Letrozole
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Complete Clinical Response in Locally Advanced Metastatic de novo Breast Cancer after Front-Line Treatment with Ribociclib/Letrozole within the RIBANNA Study

Subject Area:
Oncology , Women's and Children's Health
Christian Rudlowski, Nina Beermann, Lena Leitzen, Benno Nuding
Journal: Breast Care
Breast Care (2020) 15 (3): 289–293.
https://doi.org/10.1159/000502565
Published Online: 17 September 2019
...Christian Rudlowski; Nina Beermann; Lena Leitzen; Benno Nuding Introduction: Ribociclib is an orally bioavailable cyclin-dependent kinase 4/6 inhibitor. In combination with aromatase inhibitor letrozole, it has approval for treatment of hormone receptor positive (HR+) and human epidermal growth...
View articletitled, Complete Clinical Response in Locally Advanced Metastatic de novo Breast Cancer after Front-Line Treatment with Ribociclib/Letrozole within the RIBANNA Study
Open the PDF for Complete Clinical Response in Locally Advanced Metastatic de novo Breast Cancer after Front-Line Treatment with Ribociclib/Letrozole within the RIBANNA Study in another window
Journal Articles

Cost-Benefit Analysis of Endocrine Therapy in the Adjuvant Setting for Postmenopausal Patients with Hormone Receptor-Positive Breast Cancer, Based on Survival Data and Future Prices for Generic Drugs in the Context of the German Health Care System

Subject Area:
Oncology , Women's and Children's Health
Michael P. Lux, Claudia Reichelt, Jon Karnon, Thorsten D. Tänzer, Dragan Radosavac, Peter A. Fasching, Matthias W. Beckmann, Falk C. Thiel
Journal: Breast Care
Breast Care (2011) 6 (5): 381–389.
https://doi.org/10.1159/000333118
Published Online: 13 October 2011
... extrapolated to overall survival. The present study calculates the cost-effectiveness of 5 years of letrozole versus tamoxifen versus anastrozole in the context of the German health care system, using survival data from the Breast International Group (BIG) 1-98 study and the Arimidex, Tamoxifen, Alone...
View articletitled, Cost-Benefit Analysis of Endocrine Therapy in the Adjuvant Setting for Postmenopausal Patients with Hormone Receptor-Positive Breast Cancer, Based on Survival Data and Future Prices for Generic Drugs in the Context of the German Health Care System
Open the PDF for Cost-Benefit Analysis of Endocrine Therapy in the Adjuvant Setting for Postmenopausal Patients with Hormone Receptor-Positive Breast Cancer, Based on Survival Data and Future Prices for Generic Drugs in the Context of the German Health Care System in another window
Journal Articles

Is Endocrine Therapy Really Pleasant? Considerations about the Long-Term Use of Antihormonal Therapy and Its Benefit/Side Effect Ratio

Subject Area:
Oncology , Women's and Children's Health
Peter Blaha, Ruth Exner, Andrea Dal Borgo, Sinda Bigenzahn, Peter Panhofer, Otto Riedl, Sebastian Schoppmann, Thomas Bachleitner-Hofmann, Emanuel Sporn, Ursula Pluschnig, Florian Fitzal, Guenther Steger, Raimund Jakesz, Peter Dubsky, Michael Gnant
Journal: Breast Care
Breast Care (2009) 4 (3): 155–161.
https://doi.org/10.1159/000227829
Published Online: 23 June 2009
...-Hofmann Emanuel Sporn Ursula Pluschnig Florian Fitzal Guenther Steger Raimund Jakesz Peter Dubsky Michael Gnant Department of Surgery, Medical University of Vienna, Austria Key Words Endocrine therapy · Breast cancer · Tamoxifen · Aromatase inhibitors · Anastrozole · Letrozole · Exemestane · Side effects...
View articletitled, Is Endocrine Therapy Really Pleasant? Considerations about the Long-Term Use of Antihormonal Therapy and Its Benefit/Side Effect Ratio
Open the PDF for Is Endocrine Therapy Really Pleasant? Considerations about the Long-Term Use of Antihormonal Therapy and Its Benefit/Side Effect Ratio in another window
Journal Articles

Adjuvant Endocrine Therapy in Early Postmenopausal Breast Cancer

Subject Area:
Oncology , Women's and Children's Health
Christoph Mundhenke, Christian Schem, Walter Jonat
Journal: Breast Care
Breast Care (2008) 3 (5): 317–324.
https://doi.org/10.1159/000155548
Published Online: 21 October 2008
...) letrozole and anastrozole offer greater protection against recurrence than tamoxifen in upfront substitution strategies in the first 5 years. Similarly, changeover to an AI (exemestane or anastrozole) after 2–3 years of tamoxifen has been more efficient to prevent recurrence than 5 years of tamoxifen. Most...
View articletitled, Adjuvant Endocrine Therapy in Early Postmenopausal Breast Cancer
Open the PDF for Adjuvant Endocrine Therapy in Early Postmenopausal Breast Cancer in another window